PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) with Megapharm in Israel


January 2, 2018

MADRID, January 2, 2018 /PRNewswire/ —


PharmaMar (MCE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian Authority.


(Logo: )

According to the agreement Megapharm will register Aplidin® on behalf of PharmaMar and distribute the compound in both regions. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.


Aplidin® is PharmaMar´s second most advanced anticancer drug which is currently under development for the treatment of multiple myeloma and angioimmunoblastic T-cell lymphoma. The Company announced in March 2016 that plitidepsin has shown positive results in a pivotal Phase III clinical trial (ADMYRE) for multiple myeloma[i].


According to Luis Mora, Managing Director of PharmaMar´s Oncology Business Unit, “we are about to address our first strategic alliance with Megapharm for the commercialization of Aplidin® formultiple myeloma in Israel and the territory known as the Palestinian Authority. Our commitment is to bring a novel and first-in-class therapy to patients in need.”


Miron Drucker, CEO of Megapharm, stated that “the agreement between PharmaMar and Megapharm offers a major advance for healthcare in our territory as Aplidin® provides a novel mechanism of action for treating multiple myeloma; we hope to bring access to the most innovative treatments to our patients in Israel and the territory known as the Palestinian Authority”.


Posted in: Commercial, Licensing

Post a Comment

You must be logged in to post a Comment.